News und Analysen
Transgene Appoints Steven Bloom as Chief Business Officer
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced today that it has appointed
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Pfizer’s Hospital leadership team – Angela Lukin, Global President; Annaliesa Anderson
Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”) therapeutics for the
STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 23, 2022
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
NanoString to Webcast Presentation from the 11th Annual SVB Leerink Global Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.
“I am immensely proud of
QIAGEN übertrifft Prognose für viertes Quartal und das Gesamtjahr 2021 und erzielt Umsatzwachstum von 22% (CER) mit Nicht-COVID-Produkten
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse für das vierte Quartal und das Gesamtjahr 2021 bekannt.
Der Konzernumsatz stieg im vierten Quartal 2021 gegenüber
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2021.
Net sales for Q4 2021 rose 2% (+4% CER) to $582 million from Q4 2020, well
Premier Inc. to Participate in 2022 SVB Leerink Global Healthcare Conference on February 16, 2022
Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in a virtual fireside chat
Humana Specialty Pharmacy Expands Access to New Cancer Treatment Options
Humana Specialty Pharmacy has announced two significant additions to its comprehensive, personalized and targeted oncology therapies.
Patients can now receive the following drugs, delivered to
Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced an update to
Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be
Premier Inc. Receives 2022 Best in KLAS Award for Value-Based Care Consulting
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been awarded the 2022 Best in KLAS designation for Value-Based Care Consulting. The award was announced in
Pfizer Reports Fourth-Quarter and Full-Year 2021 Results
Pfizer Inc. (NYSE: PFE) reported strong financial results for fourth-quarter and full-year 2021 and provided 2022 total company financial guidance(4). In addition, Pfizer raised its previous 2022
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or
Chemed To Report Fourth-Quarter 2021 Earnings February 24, Related Conference Call To Be Held On February 25
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2021, on Thursday, February 24, 2022, following the close of trading
Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
NanoString to Release Fourth Quarter and Fiscal Year 2021 Operating Results and Host Conference Call on Tuesday, March 1, 2022
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will release fourth quarter and
Lysogene Provides Medical Update
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today provides a medical update.
First
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has gained additional momentum with the approval of the fourth
QIAGENs neue Generation des QuantiFERON-TB-Tests erhält Zulassung in China und erneute WHO-Empfehlung
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass seine Tuberkulose (TB)-Testlösung QuantiFERON weiter an Dynamik gewonnen hat, nachdem die vierte Generation des
Agilent Highlights Integrated Automation Solutions at SLAS 2022
Agilent Technologies Inc. (NYSE: A) highlights innovative laboratory automation solutions at the SLAS2022 International Conference and Exhibition held February 5 through February 9, 2022, at the
DGAP-Adhoc: Evotec SE: Bayer stellt den klinischen Entwicklungskandidaten Eliapixant (BAY1817080) ein; Evotec erhält Rechte für alle P2X3-Assets zurück
DGAP-Adhoc: Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets
